We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

688047:SSELoongson Technology Corp. Ltd. Class A Analysis

Data as of 2026-03-17 - not real-time

CN¥146.12

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Loongson’s shares are trading at CNY 146.12, which sits below the 20‑day (CNY 153.87) and 50‑day (CNY 154.55) simple moving averages, signaling short‑term weakness. The bearish MACD (‑2.53 line vs. ‑1.60 signal) and a neutral RSI of 43 reinforce downside momentum, while the 30‑day volatility of 52% and a negative beta of ‑0.17 suggest the stock is highly reactive to market swings. Technical support lies near CNY 141.48 and resistance at CNY 167.77, and the market’s “Extreme Greed” sentiment (79.45 on the Fear‑Greed Index) may be inflating price expectations.
Fundamentally, the company posted CNY 635 million in revenue with a robust 44.9% growth rate, yet it is operating at a steep loss – operating margin of ‑30.5% and net profit margin of ‑71.4%, with negative EPS of ‑1.68. Valuation multiples are extreme (P/B 22.9×, P/S 92.2×) and the debt‑to‑equity ratio of 2.06, despite a solid cash balance of CNY 516 million, underscores financial strain. No dividend is paid, and cash‑flow generation is nil. These dynamics paint a picture of an overvalued, high‑risk semiconductor play despite top‑line growth.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below 20‑day and 50‑day SMAs
  • Bearish MACD histogram
  • Extreme valuation multiples (P/B, P/S)

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth (44.9%)
  • Persistent operating losses and negative cash flow
  • High regulatory and sector headwinds in Chinese semiconductor market

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Strategic importance of domestic processor technology
  • Substantial cash cushion versus modest debt
  • Unclear path to profitability and continued overvaluation

Key Metrics & Analysis

Financial Health

Revenue Growth44.90%
Profit Margin-71.41%
ROE-16.52%
Debt/Equity2.06
P/B Ratio22.9
Industry P/E34.2

Technical Analysis

TrendNeutral
RSI43.4
SupportCN¥141.48
ResistanceCN¥167.77
MA 20CN¥153.87
MA 50CN¥154.55
MA 200CN¥139.35
MACDBearish
VolumeIncreasing
Fear & Greed Index79.45

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta-0.17
Volatility52.10%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.